Pricing Log in Create free account
Saturday 17 October 2026 Export MDT’s income statement to Excel — free account

Medtronic PLC

MDT Healthcare Medical Devices

Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025. In the quarter to July 2026, revenue grew 13.7%, EPS grew 42.0%, free cash flow grew 120.9% and total debt fell 1.59%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three.

94.75 0.70 −0.73%
Market cap
$122.1B
P/E
23.2×
Fwd P/E
18.7×
Dividend yield
3.02%
F-score
7/9
Altman Z
2.73
Beneish M
−2.58
Dividend safety
61/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Medtronic PLC (MDT) Business Profile

Updated before January 2025

Company Overview

Medtronic PLC (MDT) is a global leader in medical technology, services, and solutions. Founded in 1949 by Earl Bakken and Palmer Hermundslie in Minneapolis, Minnesota, the company initially focused on repairing medical equipment. Medtronic revolutionized the healthcare industry in 1957 with the invention of the first battery-powered, wearable pacemaker. Over the decades, the company has expanded its portfolio to include a wide range of innovative medical devices and therapies. Today, Medtronic is headquartered in Dublin, Ireland, and operates in over 150 countries, employing more than 95,000 people worldwide. The company is led by Chairman and CEO Geoff Martha, who assumed the role in April 2020, bringing a strong focus on innovation, digital transformation, and global healthcare access.

Core Business Segments

Medtronic operates through four primary business segments, each offering a diverse range of products and services:

1. Cardiovascular Portfolio

This segment focuses on products and therapies for heart-related conditions. Key offerings include:

  • Cardiac Rhythm Management Devices: Pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy devices.
  • Structural Heart Products: Transcatheter aortic valve replacement (TAVR) systems and surgical heart valves.
  • Coronary and Peripheral Vascular Devices: Stents, balloons, and atherectomy devices for treating vascular diseases.

2. Neuroscience Portfolio

This segment addresses neurological and spinal conditions. Key offerings include:

  • Neurostimulation Devices: Spinal cord stimulators and deep brain stimulation systems for chronic pain and movement disorders.
  • Cranial and Spinal Technologies: Surgical tools, implants, and navigation systems for spine and brain surgeries.
  • Specialty Therapies: Products for conditions like hydrocephalus and severe epilepsy.

3. Medical Surgical Portfolio

This segment focuses on minimally invasive surgical solutions. Key offerings include:

  • Surgical Instruments and Technologies: Advanced energy devices, stapling systems, and robotic-assisted surgery platforms like the Hugo™ RAS system.
  • Gastrointestinal and Hepatology Products: Endoscopy systems and devices for diagnosing and treating digestive diseases.
  • Respiratory and Monitoring Solutions: Ventilators, pulse oximeters, and capnography systems.

4. Diabetes Portfolio

This segment provides solutions for diabetes management. Key offerings include:

  • Insulin Pumps: MiniMed™ insulin pump systems for continuous insulin delivery.
  • Continuous Glucose Monitoring (CGM) Systems: Guardian™ CGM systems for real-time glucose monitoring.
  • Diabetes Management Software: Digital tools and apps for personalized diabetes care.

Business Model

Medtronic’s business model integrates innovative medical devices, comprehensive services, and digital health solutions to improve patient outcomes. The company generates revenue through the sale of medical devices, consumables, and software, as well as through service contracts and consulting. Medtronic invests heavily in research and development (R&D), allocating approximately 7-8% of its annual revenue to innovation. The company also collaborates with healthcare providers, governments, and other stakeholders to expand access to its therapies globally. Medtronic’s focus on value-based healthcare ensures that its products and services deliver measurable clinical and economic benefits.

Strategic Direction

Medtronic’s strategic priorities include:

  • Innovation: Developing next-generation medical technologies, including AI-powered devices and robotic-assisted surgery platforms.
  • Global Expansion: Increasing its presence in emerging markets, where healthcare access is growing.
  • Sustainability: Achieving carbon neutrality in its operations by 2030 and reducing waste across its supply chain.
  • Digital Transformation: Leveraging data analytics, remote monitoring, and telehealth solutions to enhance patient care.
  • Portfolio Diversification: Expanding into adjacent markets, such as renal care and oncology, through acquisitions and partnerships.

Competitive Landscape

Medtronic faces competition from several major players in the medical technology industry, including:

  • Johnson & Johnson: Competes in surgical instruments, orthopedics, and cardiovascular devices.
  • Boston Scientific: A key competitor in cardiac rhythm management, neurostimulation, and vascular devices.
  • Abbott Laboratories: Competes in diabetes care, cardiovascular devices, and diagnostics.
  • Stryker Corporation: Focuses on orthopedic implants and surgical technologies.
  • Zimmer Biomet: Specializes in musculoskeletal healthcare solutions.

Despite intense competition, Medtronic maintains a competitive edge through its broad product portfolio, strong R&D capabilities, and global reach.

Risk Factors

Medtronic faces several risks that could impact its business:

  • Regulatory Compliance: Strict regulatory requirements for medical devices can delay product approvals and increase costs.
  • Market Dependence: Reliance on a few key products for a significant portion of revenue.
  • Supply Chain Disruptions: Global supply chain challenges, including shortages of raw materials and components.
  • Pricing Pressures: Increasing demand for cost-effective healthcare solutions from governments and insurers.
  • Litigation Risks: Exposure to product liability lawsuits and intellectual property disputes.

Recent Developments

  • Hugo™ RAS System: Medtronic launched its robotic-assisted surgery platform, Hugo™, to compete in the growing market for minimally invasive surgeries.
  • Acquisitions: The company acquired Intersect ENT to expand its ear, nose, and throat (ENT) portfolio.
  • COVID-19 Response: Medtronic ramped up production of ventilators and other critical care products during the pandemic.
  • Digital Health Initiatives: Launched AI-powered solutions for remote patient monitoring and chronic disease management.

Investment Considerations

Strengths:

  • Market leader with a diverse product portfolio.
  • Strong focus on innovation and R&D.
  • Global presence with operations in over 150 countries.
  • Commitment to sustainability and value-based healthcare.

Risks:

  • Exposure to regulatory and legal challenges.
  • Dependence on key products for revenue.
  • Vulnerability to economic and geopolitical uncertainties.

Conclusion

Medtronic PLC is a global leader in medical technology, offering a diverse range of innovative products and services. With a strong focus on R&D, sustainability, and digital transformation, the company is well-positioned to address the evolving needs of the healthcare industry. While it faces challenges such as regulatory compliance and market competition, Medtronic’s strategic initiatives and global reach provide a solid foundation for future growth.